A mother's voice is the first thing we hear from the time we exit the womb. And its the voice we continue to hear throughout our lives. We model our mother's voice when we first learn to talk. The same voice guides us as we begin to walk. It warns you of potential harm and radiates warmth when you need consolation.
On Monday, April 27, 2015, American theatre director, choreographer, film director, and performer Susan Stroman hosted the ADDF's Ninth Annual Connoisseur’s Dinner. More than $2.8 million was raised to support Alzheimer's drug discovery and development.
On Wednesday, April 15, 2015, renowned journalist and NPR host Diane Rehm welcomed guests to the ADDF's Fifth Annual Great Ladies Luncheon & Fashion Show in Washington, DC. Rehm, who has long used her public platform to raise awareness for Alzheimer’s disease, spoke eloquently about the need to increase support for drug discovery for Alzheimer's.
Asceneuron SA, an emerging leader in the development of novel, oral small molecule therapeutics targeting tauopathies for Alzheimer’s and related neurodegenerative diseases, today announced that the ADDF awarded it a $325,000 grant to support the development of Asceneuron’s tau modulators.
The ADDF announced today that it has awarded $1 million to GliaCure, a biotechnology company developing innovative therapies based on glial targets, to co-fund a Phase 1b clinical trial in patients with mild to moderate Alzheimer’s disease. The study, which recently began screening volunteers, will determine the safety and tolerability of GliaCure’s primary clinical candidate, GC021109.
Alzheimer’s Drug Discovery Foundation an Official Charity Partner of 2015 TCS New York City Marathon
The ADDF is pleased to announce that it is an Official Charity Partner of the 2015 TCS New York City Marathon.
The ADDF and Pfizer’s Centers for Therapeutic Innovation (CTI) announced today a collaboration designed to advance the development of new small-molecule drugs for Alzheimer’s disease and related dementias.
The ADDF announced today a $900,000 grant to AgeneBio, a pharmaceutical company developing innovative therapies for neurologic and psychiatric diseases. The grant will support the initiation of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment (aMCI).
The ADDF has awarded a follow-on grant to Axxam to further develop small molecule drugs to treat Alzheimer’s disease by targeting inflammation. This grant follows two previous awards by ADDF to Axxam in 2011 and 2013. The award will continue to fund a drug discovery project to identify compounds that selectively block the purinergic receptor, P2X7, which is involved in inflammation in the brain.
Today, the ADDF and the Alzheimer’s Society UK announced new funding to explore the possibility of using a commonly prescribed drug which treats erectile dysfunction as the next treatment for dementia. Tadalafil is to be one of the major research programs funded by the two charities in a cross-Atlantic research partnership.